News and Trends 16 Oct 2017 French Biotech Lifted by €7M Series A to Develop New Antibiotics Antabio has taken a step towards tackling antibiotic resistance by securing a €7.3M Series A. The funding will accelerate the company’s candidate through a Phase I clinical trial. Antabio is a French biopharma that focuses on one of the world’s biggest crises – antibiotic resistance. The company has raised €7.3M in Series A of fundraising, which it will use to […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […] October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 New Stem Cells Could Take Cell Research and Therapies to the Next Level British researchers have created a new type of stem cell in mice. It has even greater potential than current cell lines in research and in the clinic. Stem cells have huge potential in research and therapeutics and overcome the limitations of current cell lines – embryonic and induced pluripotent stem cells. Findings published in Nature report that researchers at […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Why Might Biotechs Lose Easy Access to Scientific Papers? Five publishers have ordered ResearchGate to take down articles. Researchers might continue to get around the paywall with Sci-Hub and other initiatives. ResearchGate, described as ‘Facebook for scientists’, has over 13 million members. It has raised more than $80M (€68M) from investors including Bill Gates and the Wellcome Trust. But, five scientific publishers including Elsevier and Wiley have clubbed […] October 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world. Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by […] October 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 Can Catalonia Keep its Record Biomedical Investment After the Bank Drain? A new study reveals Catalonia achieved a record investment in biomedicine last year. But can the region keep it up after its main banks moved out last week? CataloniaBio has released an annual report on the performance of the biomedical sector in Catalonia. The results reveal that the sector raised a record €153M in 2016, an […] October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 This New Approach Simplifies Protein Analysis Analyzing your protein sample can be a right hassle. It takes time, energy and a LOT of nerves. Especially, when the experiment has not worked out the way one wanted it to. But there is a way around it, and this company has found the solution! The use of protein biomarkers has become an essential […] October 12, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M VirionHealth kicks off the development of a broad spectrum antiviral for all influenza strains and other viruses like RSV with a £13M investment in Series A. VirionHealth is developing a new type of antiviral therapy with the potential to target multiple types of viruses at once. The treatment is based on natural antivirals called defective interfering viruses. They consist […] October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2017 Deadly Parasite Could be Stopped by Scottish Researchers’ Discovery A study in Scotland has improved our understanding of how a dangerous parasite functions, creating a new target for combatting deadly infections. Research from the University of Edinburgh has identified a therapeutic target in Leishmania, a parasite that infects 1 million people each year, resulting in 20,000-30,000 deaths. The study, published in the Journal of Molecular Biology, used clever […] October 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2017 Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease A decade of work has culminated in researchers reconstructing a protein that is key to defending the brain against Parkinson’s disease. Researchers at the University of Dundee have made a breakthrough by uncovering the 3D structure of an enzyme, PINK1, that can protect the brain against Parkinson’s disease. The disease is characterised by the degeneration […] October 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2017 French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops gene therapies to treat genetic diseases affecting vision. The company will now start a Phase I/II clinical trial that will recruit 12 patients at the Nantes […] October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email